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Background
Anti-RNP antibody and anti-Sm antibody were identified as risk factors for Systemic Lupus 
Erythematosus (SLE) associated pulmonary arterial hypertension.1
Rinaldi et al.2 describe Saccharomyces cerevisiae mannan related SLE autoantibodies.
Vaccine antigens can result in autoimmunity due to molecular mimicry as we have seen in the case of 
Pandemrix induced narcolepsy.3
Hepatitis B vaccines, HPV vaccines and some other vaccines are produced using yeast (S. cerevisiae)4. 
Since vaccines can be contaminated with any protein from S. cerevisiae, BLASTP comparisons were 
run for the entire organism (not just mannan). Results are presented below.
SLE has been associated with the Hepatitis B and other vaccines.5,6
IOM report on vaccine adverse events 20127 says:
“Poirriez (2004) reported the absorption of antinuclear antibodies (ANAs), isolated from a single 
hepatitis B immunized patient who developed lupus, by highly concentrated vaccine antigen suggesting
mimicry between vaccine antigen and self-antigen.”
SLE has been associated with the HPV vaccine.8
SLE has been associated with the Epstein-Barr virus (EBV).9
BLASTP results for EBV are also included below.
Method
Protein sequences for the autoantigens were obtained from Uniprot.10
BLASTP methodology used was previously described.11
Results
1. Strong alignment between human U1 snRNP  1,12   and S.cerevisiae.  
U1 small nuclear ribonucleoprotein 70 kDa (human) vs. S.cerevisiae
Snp1p [Saccharomyces cerevisiae YJM270]
Sequence ID: AJR37623.1Length: 300Number of Matches: 1
Related Information
Identical Proteins-Identical proteins to EHN06639.1
Range 1: 15 to 200GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Method    Identities    Positives    Gaps
87.8 bits(216)    2e-18    Compositional matrix adjust.    67/195(34%)    105/195(53%)    22/195(11%)
Query  12   LFAPRDPIPYLPPLEKLPHEKHHNQP-YCGIAP--------YIREFEDPRDAPPPTRAET  62
                  LF PR P+ Y  P +  P+ K    P   G+A         Y+ EF  P  +P       
Sbjct  15   LFKPRPPLSYKRPTD-YPYAKRQTNPNITGVANLLSTSLKHYMEEF--PEGSP-----NN  66
Query  63   REERMERKRREKIERRQQEVETELKMWDPHNDPNAQ-GDAFKTLFVARVNYDTTESKLRR  121
                       +R E  +  KI +  Q ++  L+ W+P+ DP+ +  D ++T+F+ R+ YD  E +L++
Sbjct  67   HLQRYEDIKLSKI-KNAQLLDRRLQNWNPNVDPHIKDTDPYRTIFIGRLPYDLDEIELQK  125
Query  122  EFEVYGPIKRIHMVYSKRSGKPRGYAFIEYEHERDMHSAYKHAD---GKKIDGRRVLVDV  178
                     F  +G I++I +V  K + K +GYAFI ++       A+K      G +I GR  +VD+
Sbjct  126  YFVKFGEIEKIRIVKDKITQKSKGYAFIVFKDPISSKMAFKEIGVHRGIQIKGRVCIVDI  185
Query  179  ERGRTVKGWRPRRLG  193
                   ERGRTVK ++PRRLG
Sbjct  186  ERGRTVKYFKPRRLG  200
2. Strong alignment between human Sm B/B′  1,12   and S. cerevisiae  
Small nuclear ribonucleoprotein-associated proteins B and B' (human) vs. S. cerevisiae
Smb1p [Saccharomyces cerevisiae YJM1615]
Sequence ID: AJU45326.1Length: 196Number of Matches: 1
Related Information
Range 1: 4 to 101GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Method    Identities    Positives    Gaps
87.8 bits(216)    2e-20    Compositional matrix adjust.    45/98(46%)    62/98(63%)    12/98(12%)
Query  1    MTVGKSSKMLQHIDYRMRCILQDGRIFIGTFKAFDKHMNLILCDCDEFR-------KIKP  53
                  + V  SS++   IDY++R + QDGR++IG   AFDKHMNL+L +C E R       K++P
Sbjct  4    IQVAHSSRLANLIDYKLRVLTQDGRVYIGQLMAFDKHMNLVLNECIEERVPKTQLDKLRP  63
Query  54   -KNSKQAE----REEKRVLGLVLLRGENLVSMTVEGPP  86
                    K+SK       + EKRVLGL +LRGE ++S  VE  P
Sbjct  64   RKDSKDGTTLNIKVEKRVLGLTILRGEQILSTVVEDKP  101
3. Strong and comparable alignment between human SNRPD1  1,12   vs. both S. cerevisiae   and EBV 
SNRPD1 (human) vs. S. cerevisiae
Snf2p [Saccharomyces cerevisiae YJM1386]
Sequence ID: AJU00532.1Length: 1708Number of Matches: 10
Related Information
Range 1: 1509 to 1527GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Identities    Positives    Gaps
59.2 bits(132)    2e-11    19/19(100%)    19/19(100%)    0/19(0%)
Query  3     GRGRGRGRGRGRGRGRGRG  21
                    GRGRGRGRGRGRGRGRGRG
Sbjct  1509  GRGRGRGRGRGRGRGRGRG  1527
SNRPD1 (human) vs. Epstein-Barr virus (EBV)
EBNA-1 [Cynomolgus Epstein-Barr Virus Si-IIA]
Sequence ID: BAB03282.1Length: 588Number of Matches: 11
Related Information
Range 1: 267 to 293GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Identities    Positives    Gaps
58.7 bits(131)    3e-11    22/27(81%)    22/27(81%)    5/27(18%)
Query  3    GRGRGRG--RGRGRGRGRGRG---GPR  24
                  GRGRGRG  RGRGRGRGRGRG   GPR
Sbjct  267  GRGRGRGGSRGRGRGRGRGRGRGQGPR  293
4. Significant and comparable alignment between human SNRPD1  1,12   vs. both Hepatitis B virus and HPV 
Note: Hepatitis B and HPV vaccines are manufactured using recombinant technology to produce virus like particles 
(VLP).13–15 The BLAST database only contains the whole virus entries, not VLPs.
Therefore, the Hepatitis B core protein result below may only apply to Hepatitis B infections and not to Hepatitis B 
immunization with recombinant vaccines.
SNRPD1 (human) vs. Hepatitis B virus
core protein [Hepatitis B virus]
Sequence ID: ANQ90213.1Length: 185Number of Matches: 2
Related Information
Range 1: 150 to 160GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Identities    Positives    Gaps
29.5 bits(62)    0.017    10/12(83%)    10/12(83%)    1/12(8%)
Query  14   RGRGRGRGGPRR  25
                   RGRGRGR  PRR
Sbjct  150  RGRGRGR-SPRR  160
SNRPD1 (human) vs. HPV virus
E2 [Human papillomavirus]
Sequence ID: AQM73700.1Length: 433Number of Matches: 1
Related Information
Range 1: 289 to 310GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Identities    Positives    Gaps
27.4 bits(57)    0.097    14/24(58%)    14/24(58%)    5/24(20%)
Query  4    RGRGRGRGRGRG---RGRGRGGPR  24
                  RG GR RG GRG   R R R G R
Sbjct  289  RG-GR-RGSGRGPLTRSRSRSGSR  310
5. Significant and comparable alignment between Human Sm B/B′  1,9,12   target vs. both S. cerevisiae   and EBV. 
PPPGMRPP9,16 vs. S. cerevisiae
chromosome stability-related protein [Saccharomyces cerevisiae YJM789]
Sequence ID: EDN59297.1Length: 482Number of Matches: 1
See 32 more title(s)
Related Information
Identical Proteins-Identical proteins to EDN59297.1
Range 1: 280 to 286GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Identities    Positives    Gaps
21.4 bits(43)    23    6/7(86%)    6/7(85%)    0/7(0%)
Query  1    PPPGMRP  7
                  PPPGM P
Sbjct  280  PPPGMNP  286
PPPGMRPP9,16 vs EBV
EBNA1 [Human gammaherpesvirus 4]
Sequence ID: ALV83108.1Length: 685Number of Matches: 1
Related Information
Range 1: 442 to 448GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Identities    Positives    Gaps
21.0 bits(42)    33    6/7(86%)    6/7(85%)    0/7(0%)
Query  1    PPPGMRP  7
                  PPPG RP
Sbjct  442  PPPGRRP  448
6. Significant alignment between the peptide sequence leading to Ro autoimmunity in SLE (TKYKQRNGWSHK)  9  and S.  
cerevisiae.
TKYKQRNGWSHK9 vs. S. cerevisiae
Bag7p [Saccharomyces cerevisiae YJM1388]
Sequence ID: AJU01372.1Length: 404Number of Matches: 1
See 2 more title(s)
Related Information
Identical Proteins-Identical proteins to AJU01372.1
Range 1: 384 to 392GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Identities    Positives    Gaps
21.0 bits(42)    76    6/9(67%)    6/9(66%)    0/9(0%)
Query  1    TKYKQRNGW  9
                  TK KQR  W
Sbjct  384  TKHKQRQSW  392
7. Significant alignment between the cross-reactive epitope of EBNA-1 (GGSGSGPRHRDGVRR)  9   and S. cerevisiae  . 
 GGSGSGPRHRDGVRR9  vs. S. cerevisiae
Rfm1p [Saccharomyces cerevisiae YJM1463]
Sequence ID: AJU10280.1Length: 310Number of Matches: 1
Related Information
Range 1: 191 to 196GenPeptGraphicsNext MatchPrevious Match
Alignment statistics for match #1
Score    Expect    Identities    Positives    Gaps
20.2 bits(40)    252    5/6(83%)    6/6(100%)    0/6(0%)
Query  10   RDGVRR  15
                 RDG+RR
Sbjct  191  RDGIRR  196
Conclusion
Saccharomyces cerevisiae (yeast) contaminated vaccines such as Hepatitis B and HPV vaccines can 
cause the synthesis of SLE associated autoantibodies. S. cerevisiae and Epstein-Barr virus are 
comparable in molecular mimicry of multiple self antigens. So they seem equally capable of causing 
SLE autoimmunity.
Action
All contaminating proteins in vaccines must be removed immediately.17 All proteins in vaccines needed
for disease protection must also be thoroughly scrutinized for molecular mimicry that can result in 
allergic or autoimmune diseases.
References
1. Wang J, Qian J, Wang Y, Zhao J, Wang Q, Tian Z, et al. Serological biomarkers as risk factors of SLE-
associated pulmonary arterial hypertension: a systematic review and meta-analysis. Lupus. SAGE 
Publications; 2017 Apr 14;0961203317702255. 
2. Rinaldi M, Perricone R, Blank M, Perricone C, Shoenfeld Y. Anti-saccharomyces cerevisiae 
autoantibodies in autoimmune diseases: From bread baking to autoimmunity. Clinical Reviews in Allergy
and Immunology. 2013. p. 152–61. 
3. Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, et al. Antibodies to influenza 
nucleoprotein cross-react with human hypocretin receptor 2 (ABSTRACT ONLY). Sci Transl Med. 
2015;7(294):294ra105–294ra105. 
4. Vaccine Excipient & Media Summary [Internet]. 2015 [cited 2016 Jan 16]. Available from: 
http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf
5. Poirriez J. A preliminary experiment of absorption of antinuclear antibodies by the hepatitis B vaccine 
components, in a case of neurolupus. Vaccine. Netherlands; 2004 Aug;22(23-24):3166–8. 
6. Wang B, Shao X, Wang D, Xu D, Zhang J-A. Vaccinations and risk of systemic lupus erythematosus and 
rheumatoid arthritis: A systematic review and meta-analysis. Autoimmun Rev. Netherlands; 2017 
Jul;16(7):756–65. 
7. Stratton K, Ford A, Rusch E, Clayton EW. Adverse Effects of Vaccines : Evidence and Causality. Injury. 
2011. 0-24 p. 
8. Soldevilla HF, Briones SFR, Navarra S V. Systemic lupus erythematosus following HPV immunization or
infection? Lupus. England; 2012 Feb;21(2):158–61. 
9. Toussirot É, Roudier J. Epstein&#x2013;Barr virus in autoimmune diseases. Best Pract Res Clin 
Rheumatol. Elsevier; 2017 Apr 29;22(5):883–96. 
10. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017 Jan 4;45(D1):D158–69. 
11. Arumugham V. Significant protein sequence alignment between peanut allergen epitopes and vaccine 
antigens [Internet]. 2016. Available from: https://www.zenodo.org/record/1034555#.WevzcB9ghBI
12. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity. 
Taylor & Francis; 2005 Feb 1;38(1):47–54. 
13. Engerix B Package Insert [Internet]. [cited 2016 May 8]. Available from: 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf
14. Gardasil Package Insert [Internet]. Available from: 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
15. Recombivax HB Package Insert [Internet]. [cited 2016 May 8]. Available from: 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM110114.pdf
16. Füst G. The role of the Epstein–Barr virus in the pathogenesis of some autoimmune disorders – 
Similarities and differences. Eur J Microbiol Immunol (Bp). 
journals@akkrt.huhttp://www.akademiaikiado.hu: Akadémiai Kiadó; 2011 Dec 23;1(4):267–78. 
17. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP—an ultimate solution for 
vaccine-related gelatin allergy. Biologicals. 2003;31(4):245–9. 
